Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 75Genitourinary 40Thoracic 18Other hematologic neoplasm 17Sarcoma 16Breast 16Dermatologic 11Head & Neck 9CNS 9Endocrine 8Lymphoid 7Gynecologic 7Tumor-Agnostic 4Myeloid 4Plasma cell 3NET 2Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1

Interventions

pembrolizumab 26Pemetrexed 26Cisplatin 25Nivolumab 22Carboplatin 16Paclitaxel 14Gemcitabine 12Ipilimumab 11tislelizumab 8durvalumab 8Ramucirumab 8Docetaxel 8talazoparib 7Fluorouracil 7Radiotherapy 6Capecitabine 6tremelimumab 5cobimetinib 5atezolizumab 5adavosertib 5Radiosurgery 5Cyclophosphamide 5Bevacizumab 5olaparib 4avelumab 4Temozolomide 4Sunitinib 4Specimen Handling 4Platinum 4PM 01183 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sorafenib × Other solid neoplasm × Clear all
NCT00810394 2018-01-10

Sorafenib in Treating Patients With Advanced Malignant Solid Tumors

University of California, Davis

Phase 2 Completed
50 enrolled 6 charts
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡